Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5924911 | 0.85 | MME (1.00) | MME | |
| SCHEMBL5924871 | 0.85 | MME (1.00) | MME | |
| SCHEMBL5924879 | 0.85 | MME (1.00) | MME | |
| SCHEMBL7450171 | 0.80 | MME (0.67) | MME | |
| SCHEMBL7449713 | 0.76 | MME (0.61) | MME | |
| SCHEMBL7442734 | 0.74 | MME (0.73) | MME | |
| SCHEMBL7442730 | 0.74 | MME (0.73) | MME | |
| SCHEMBL5924940 | 0.73 | MME (1.00) | MME | |
| SCHEMBL5924934 | 0.73 | MME (1.00) | MME | |
| SCHEMBL5924965 | 0.73 | MME (1.00) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070499-A1 | Compounds for the treatment of female sexual dysfunction | PFIZER INC. | 2005-03-31 | — | — | US | disclosed |
| EP-1097719-B1 | NEP inhibitors for the treatment of female sexual dysfunction | PFIZER LTD (GB) | 2004-12-22 | — | — | EP | disclosed |
| US-20040254153-A1 | Compounds for the treatment of female sexual dysfunction | PFIZER INC | 2004-12-16 | — | — | US | disclosed |
| EP-1481667-A1 | NEP inhibitors for the treatment of female sexual dysfunction | Pfizer Limited (GB) | 2004-12-01 | — | — | EP | disclosed |
| US-6734186-B1 | PHOSPHODIESTERASE 2 INHIBITOR | PFIZER INC. | 2004-05-11 | — | — | US | disclosed |
| CN-1438991-A | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER CIMITED (US) | 2003-08-27 | — | — | CN | disclosed |
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER, INC. | 2002-05-02 | — | — | US | disclosed |
| EP-1097707-A1 | Treatment of female sexual dysfunction | Pfizer Limited (GB) | 2001-05-09 | — | — | EP | disclosed |
| EP-1097719-A1 | NEP inhibitors for the treatment of female sexual dysfunction | Pfizer Limited (GB) | 2001-05-09 | — | — | EP | disclosed |
| EP-1097706-A1 | Phosphodiesterase inhibitors for the treatment of female sexual dysfunction | Pfizer Limited (GB) | 2001-05-09 | — | — | EP | disclosed |
| EP-1097718-A1 | NPY antagonists for the treatment of female sexual dysfunction | Pfizer Limited (GB) | 2001-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254153-A1 | Compounds for the treatment of female sexual dysfunction | FSHR, SHBG, PDE3A | MME 2886/4885 |
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | ENGASE, ENPEP, CPN1 | MME 7/4885 |
| US-20050070499-A1 | Compounds for the treatment of female sexual dysfunction | FSHR, SHBG, PDE3A | MME 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.